On May 28, Guardant Health rose 5.87% in pre-market trading, trading at $127.78/share, with trading volume of $84,800.

On the news front, the company announced that its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines. The guidelines recommend Shield as an option for patients who decline or have not completed stool-based or visual examination screening tests for colorectal cancer, further validating the company's clinical value in the liquid biopsy space.

This development comes shortly after another significant milestone for the company. On May 21, the U.S. Food and Drug Administration approved its Guardant360 Liquid CDx liquid biopsy test as a companion diagnostic tool for multiple therapies in non-small cell lung cancer and colorectal cancer. That test integrates genomic and epigenomic analysis through a single blood draw, with genomic coverage expanded 100-fold compared to the previously approved version, delivering results within seven days.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)